Which Part of Your Label Is the Principal Display Panel?

The Supplement Labeling Lab | Week 2

When you look at a supplement bottle, which part of the label do you see first?

That sounds like a design question. But in dietary supplement labeling, it is also a regulatory one.

The principal display panel (PDP) is the part of the package most likely to be displayed, presented, shown, or examined under customary conditions of retail sale. In practical terms, it is generally the front of the package. Some packages may have more than one principal display panel, depending on their design. And that panel has specific requirements.

Two key components belong on the PDP

1. Statement of identity

The statement of identity tells consumers what the product is. For dietary supplements, this generally means identifying the product as a dietary supplement or using an appropriate alternative, such as “Calcium Supplement” or “Herbal Supplement,” when permitted.

A product name alone may not be enough. A creative name like “Lake Cascade Botanical Support” can help distinguish a product on the shelf, but it doesn’t necessarily tell consumers what the product is.

2. Net quantity of contents

The net quantity statement tells consumers how much product the package contains. Depending on the product, this may be expressed by weight, volume, numerical count, or an appropriate combination.

Its placement and presentation matter. The statement generally must appear as a distinct item in the bottom 30% of the PDP, subject to applicable exceptions. It must also be legible and presented in accordance with the applicable requirements.

A quick example

Imagine a Lake Cascade Nutrition bottle labeled “Botanical Support” in large, bold lettering.

The design looks great. The product name is prominent. But if the appropriate statement of identity is missing—or the net quantity statement is incorrectly placed—the front panel may still have a compliance problem.

The lesson? Don’t confuse prominent branding with required labeling information.

The takeaway

When reviewing a supplement label, start by identifying the PDP. Then check the statement of identity and net quantity of contents before moving on to the other panels.

A strong design attracts attention. A systematic label review helps ensure the required information is there, too.

Next week: We’ll look more closely at the statement of identity—and why the name consumers remember isn’t always the name the label needs.

Need help reviewing your dietary supplement label? Dietary Supplement Experts (DSE) helps businesses identify labeling issues and assess compliance before artwork approval and product launch.


Sources & Further Reading

Is your label compliant?

Your Supplement Label Has a Job to Do. Is It Doing It?

The Supplement Labeling Lab | Week 1

A dietary supplement label does more than tell consumers what’s inside the bottle. It identifies the product, communicates important information, provides required declarations, and helps consumers understand how to use the product. Each of those jobs comes with rules.

A label can look polished, professional, and ready for the printer while still having compliance problems. That’s why reviewing dietary supplement labels requires more than checking spelling or making sure the Supplement Facts panel looks right.

A good label review starts with understanding what the label is required to do.

Start with the panels

Dietary supplement labels have different areas, each with its own requirements.

The Principal Display Panel (PDP) is generally the part of the package most likely to be seen by consumers at retail. Among other requirements, it must display the statement of identity and net quantity of contents.

The Information Panel (IP) is generally the panel immediately contiguous and to the right of the PDP, subject to applicable exceptions. Required information may include Supplement Facts, the ingredient statement, and the name and place of business of the manufacturer, packer, or distributor.

Other label areas may contain directions, warnings, claims, and additional information. These areas deserve careful review, too. Claims and other statements can create compliance concerns even when the required label components appear to be in order.

Knowing where these areas begin and end is a useful first step. But identifying the panels is only the beginning. The content, wording, placement, and presentation of required information matter, too.

A simple example

Imagine a Lake Cascade Nutrition supplement bottle with attractive front-label artwork, a clean Supplement Facts panel, and a professionally formatted ingredient list.

Everything looks good.

But has anyone verified that the statement of identity meets applicable requirements? Is the net quantity statement presented correctly? Are the ingredients declared appropriately? Have the required label statements been included and placed correctly? Does the product require a warning that hasn’t made it onto the label?

A designer can produce beautiful artwork without necessarily knowing the regulatory requirements. And a label that resembles a competitor’s label isn’t automatically compliant, either.

That’s why a systematic label review matters.

The takeaway

Before approving supplement label artwork, look beyond the design. Identify the required label components, understand the rules that apply to each, and review the complete label in context.

Over the coming weeks, DSE will break dietary supplement labeling into practical lessons, using examples, regulatory references, and real-world mistakes to explain what reviewers should look for and why it matters.

Your supplement label has a job to do. Make sure it does it correctly.

Need help reviewing your dietary supplement label? Dietary Supplement Experts (DSE) helps businesses identify labeling issues and assess compliance before artwork approval and product launch.


Sources & Further Reading

Playing Games with Ingredient Names? FDA May Not Be Amused

FDA not amusedWhen we perform dietary supplement label compliance reviews, one of the most common problems we find is surprisingly simple:

The ingredient has the wrong name.

It may be a name everyone in the industry recognizes. It may be a scientific name. It may be a marketing-friendly name. It may even be the name used by the ingredient supplier.

That doesn’t necessarily make it the right name for the label.

And this isn’t just about typos.

Ingredient naming problems can come from using an abbreviation, a trademark, a familiar nickname, the wrong botanical name, an incomplete description—or simply a name that doesn’t accurately identify the ingredient being used.

So, rather than turn this into a lesson in regulatory nomenclature, let’s look at 12 ingredient-name problems we routinely see in label reviews.

The Dirty Dozen: Ingredient Names That Can Get You Into Trouble

#What we seeWhat we would useWhy it matters
1Vitamin B1ThiaminFDA specifies nutrient nomenclature. “Vitamin B1” is a permitted synonym in certain contexts, but thiamin is the prescribed nutrient name.
2Vitamin B2RiboflavinSame problem: familiar doesn’t necessarily mean the appropriate nutrient declaration.
3Vitamin B5Pantothenic acid“Vitamin B5” is commonly understood, but FDA specifies the nutrient name.
4Vitamin B9Folate“Vitamin B9” is a common shorthand, but folate is the prescribed nutrient name.
5DHADocosahexaenoic acidAn abbreviation may tell the reader what the company means without actually identifying the dietary ingredient appropriately.
6KSM-66®Ashwagandha root extractA trademark identifies a branded ingredient, not necessarily the dietary ingredient that belongs in the Supplement Facts panel.
7Ginkgo extractGinkgo biloba leaf extract (assuming leaf as the plant part used)Botanical ingredients need appropriate identification, including the plant part.
8Panax ginsengAsian ginsengStandardized common names (SCNs) found in Herbs of Commerce are required when available. This one is also part of an Import Alert.
9Berberine hydrochloride (from barberry root extract)Berberine hydrochlorideThe isolated chemical form, dietary ingredient, and source can raise different labeling questions. Don’t assume the name on the COA is automatically the name that belongs on the label.
10Stevia leaf extract (>95% Reb A)Rebaudioside AA label name needs to accurately identify what is actually in the product—not simply the plant from which the material originated. Abbreviations are also a common issue.
11TriphalaProprietary (or Triphala) Blend, with components declared by SCNs, in descending order by weight, and with plant partsFamiliar, marketing-friendly, or traditional names aren’t necessarily the required common or usual names.
12Non-GMO pumpkin seed proteinPumpkin seed proteinAncillary ingredient information that isn’t part of a common or usual name can be considered “intervening material” and generally isn’t allowed within the ingredient declaration.

Why does this happen so often?

Part of the problem is that the supplement industry has developed its own vocabulary.

Ingredient suppliers use trade names. Scientists use chemical names. Marketers use names consumers recognize. Manufacturers copy names from specifications and COAs. And companies often look at other products on the market and assume that if everyone else is using a particular name, it must be acceptable.

That’s a dangerous assumption.

The name on a supplier specification isn’t automatically the name that belongs in the Supplement Facts panel.

The name consumers recognize isn’t automatically the name FDA expects.

And the name that appears on 500 other labels isn’t automatically compliant just because it’s on 500 other labels.

Botanicals deserve extra attention.

Botanical ingredients can be particularly tricky because the declaration may need to identify the plant using the appropriate standardized common name, as well as the plant part. FDA’s labeling guidance specifically addresses the use of Herbs of Commerce for botanical terminology.

And seemingly small differences can matter. Panax ginseng and “Asian ginseng,” for example, aren’t simply stylistic variations. The botanical name needs to accurately identify the ingredient, and standardized common names should be used when available.

The same goes for extracts.

If the material in your product is a highly purified constituent derived from a plant, you can’t necessarily label it simply by naming the plant it came from.

The source of an ingredient and the dietary ingredient itself are not always the same thing.

FDA’s guidance specifically distinguishes between a dietary ingredient and an ingredient used as its source. It also permits certain constituents to be declared under a dietary ingredient.

The stevia example is a good illustration. FDA’s 2023 warning letter to Cosmax NBT USA specifically addressed a label declaring “stevia extract (leaves)” when the company’s manufacturing documentation identified the material as Stevia leaf 97% (Rebaudioside A 97%). FDA stated that when a steviol glycoside is purified to 95% or more of a single glycoside, the specific glycoside name is the common or usual name—for example, rebaudioside A.

The takeaway

Ingredient nomenclature may seem like one of the smaller details on a supplement label.

It’s not.

A label can have the right ingredient, the right amount, and the right claim—and still have a problem because the ingredient isn’t being properly identified.

Before approving an ingredient name, ask:

Is this the actual dietary ingredient?

Is this the appropriate common or usual name?

If it’s a botanical, have we identified the correct plant and plant part?

Are we using a trademark, abbreviation, nickname, or supplier name where a proper ingredient declaration is needed?

And perhaps the most important question:

Are we using this name because it’s correct—or simply because we’re used to seeing it?

Just because FDA knows what you mean doesn’t mean FDA considers it the right name.

At Dietary Supplement Experts, ingredient nomenclature is one of the many details we examine during a comprehensive label compliance review.

Because when it comes to ingredient names, “almost right” may not be good enough.

Should You Trust AI Programs for Dietary Supplement Claims Compliance?

Over the years, we have been approached multiple times about artificial intelligence programs for reviewing and correcting dietary supplement copy for FDA compliance. We have been suggested by clients to create it. We have been asked by tech groups to co-create it. We have been pitched it by those that have attempted it. And while the thought of it can be a little exciting, that excitement quickly fades once you start mentally pressure testing the concept, and sorting through the countless ways it would be likely to fail you, and possibly increase risks while simultaneously “mitigating” risks.

Before you go off-loading your regulatory compliance onto a computer program, we have compiled a list of things you should consider. And while our rough list topped 20, we will give you our top 9.

  1. Content is King, but context is Queen. While a program might be able to scan for words and phrases in isolation, it could be difficult to recognize two things that might be okay in isolation, but create an impermissible claim when paired together.

    Example: Claim says “Supports joint comfort” with an adjacent image of an arthritic hand with red enhancements to portray pain and inflammation. The claim might be okay on its own, but quickly becomes a high-risk disease claim in the context of the image.

  2. Finding implied disease claims. You often get out of something what you put into it. As could be the case with programs looking specifically for human-inputted disease terms. An implied disease claim can be just as risky as an explicit one.

    Example: If the program screens for the terms “diabetes” and “hyperglycemia”, and overlooks the implied disease claims “our product can reduce your need to take insulin” or “improves fasting glucose and HbA1c”.

  3. Overlooking images that create disease claims. Many brands do not understand that images, vignettes, and symbols can constitute disease claims. It might be challenging enough loading a program up with words and phrases, but trusting it to catch an image of an abnormal tissue or organ is even more difficult.

    Example: Your product is for respiratory health and all copy is compliant. However, an image is used of a woman sneezing with pollens floating in the air. Would that be nuanced enough to be caught?

  4. Catching disease terms at times where they are okay. Just because a disease term is used, does not automatically mean it is non-compliant and in need of editing or removal.

    Example: You feature a customer testimonial that mentions disease, but is not making any disease claims about the product. “After COVID lockdowns, we finally returned to in-person classes at the university. Product X has helped me focus on my studies.”

  5. Not accounting for claims substantiation. Making disease claims may land you in some trouble, but making unsubstantiated claims may drain your bank. Claims must align with the support behind them. AI is not going to know if your claims are truthful, not misleading, and adequately substantiated.

    Example: Your product features the latest trending ingredient. Some of your competitors are claiming this ingredient helps with weight loss, improves sleep quality, reduces stress levels, increases energy, and so on. Nothing necessarily claiming to treat or prevent diseases. But your only substantiation is “well Brand A and Brand B say it, so it must be true.” Your risk persists.

  6. Text in images. On some advertising and distribution platforms, programs are already being used to search for higher-risk terms in copy. It did not take long for marketers to realize that they could cheat some of these systems by incorporating disease claims into images so the text cannot be found. Will programs recognize text in images (not to mention videos)?

    Example: All your copy is compliant, but you make a disease claim hidden in one of your images.

  7. Overlooking scientific references. While having scientific references on hand to support claims is critical, it might not always be the best idea to publish their citations in marketing copy. Especially if those references involve disease outcomes, and imply that a product will also impact disease. Brands have often attempted to mitigate risks in this area by omitting parts of citations such as the title, as to remove some disease words from a page. It often helps, but not always.

    Example: You have a study to support a specific claim: Zhao JV, et al. Effect of Berberine on Cardiovascular Disease Risk Factors: A Mechanistic Randomized Controlled Trial. Nutrients. 2021 Jul 26;13(8):2550. You opt to remove the title to take “cardiovascular disease” off the page and publish as: Zhao JV, et al. Nutrients. 2021 Jul 26;13(8):2550. When a program might have found the offending terms before, it would likely miss this “sanitized” version.

  8. Wordsmithing and editing can be difficult. For most disease claims, there can be an alternate phrasing applied to make them structure/function claims while keeping similar contextual meaning, still aligning with the supporting science, and satisfying both compliance and marketing folks. Sometimes these edits are easy, but other times it involves a lot of debate and creativity. It would make sense that programs could suggest changes or give guidance on flagged claims, but without full consideration, the correction might just create a whole other problem.

    Example: A program flags a claim that an ingredient of a product was shown to reduce blood pressure in a major clinical trial, and provides guidance that blood pressure claims should be written to the effect of “maintaining already healthy blood pressure in healthy individuals”. The claim gets corrected in this way, but no longer aligns with the study that might have involved a significantly hypertensive population that saw modest improvements with a treatment.

  9. Missing that human touch. Regulatory work is black and white on its face, but the grey reality involves a lot of context and nuance and consideration of individual brands’ risk tolerances. What might be a good strategy today, can change in an instant following changing laws or regulations, new guidance and policies, enforcement trends, industry trends, emerging health conditions, and so on. How often will your program update to account for the changes? And factoring back in the human touch with technologies will still be a challenge with regards to training, interpretations, user/employee turnover, marketers refusing to accept regulatory changes, and many of the normal challenges we already deal with daily without adding a computer program to the mix.

Admittedly, creating a list like this does stir some creativity, and ideas on how to overcome these challenges. However, it is still very difficult to trust that issues like these and a myriad of others will be solved in the foreseeable future. But for now, we are not suggesting that clients use artificial intelligence to write marketing copy, and we are not at all suggesting that clients trust artificial intelligence to ensure their copy is compliant.

FTC Sends Nearly 700 Letters to Brands!

On April 13th, nearly 700 companies selling dietary supplements and other health products received letters from the FTC, putting them on notice about claims being adequately substantiated and civil penalties that may occur if they are not. 

Did your brand make the list? Did your competitors’ brands make the list? Check here.

If you’d like to read the press release, or see the template for the letters sent, check here and here.

Regardless of who made the list and received the letter, the entire dietary supplement industry should be hearing the message loud and clear. And that message is to make only substantiated claims in your advertising and have adequate substantiation on hand at the time you make claims. If you are unsure how to comply with that, the FTC published a new Health Products Compliance Guidance document this past December. Clearly, they want this Guidance taken seriously.

If you received the letter, you should act fast and get your claims and substantiation lined up, as you will likely be on the front lines for a wave of enforcement likely to be coming. If you did not receive a letter, you might be a bit more under the radar, but we would advise the same thing. 

One of the things we tell clients repeatedly is that compliance can be a huge advantage, and it seems like it becomes more and more of an advantage for smart brands year after year. The truth is, most of your competitors have labels with regulatory violations that they do not know about and do not care about, a large number of your competitors have their products made in facilities that claim “cGMP-compliant” and “GMP-Certified” that fall short of the actual regulations in countless ways – usually starting right at the point of receiving raw materials, too many of your competitors are making explicit disease claims that make it difficult and unfair for you to compete, and virtually none of your competitors have adequate substantiation on hand for the claims they make in their advertising.

Yes, we are a very regulated industry, but enforcement is beyond low. And as we’ve seen with our clients time and time again over the years, having labels, cGMPs, and claims buttoned up can be a major advantage in the face of things like Amazon suddenly requiring cGMP documentation, FDA inspections, NAD cracking down on certain areas, California Prop 65 complaints, and mass letters from the FTC. What can turn into a major disruption and distraction for some brands, can also be a minor bump and chance to grab market share for other that are better prepared.

Dietary Supplement Experts has the experience in creating strategy around avoiding regulatory disruptions and distractions. We can help clean up compliance issues long before they ever become issues. You can keep selling while your competitors respond to Warning Letters, meet with lawyers, turn off ad campaigns, conduct recalls, lose customers, and wish they did things correctly earlier on.

Need claims substantiation for your product and advertising?

Not far behind dietary supplement label compliance review, one of our most common services for brands is building claims substantiation files. Here are three great reasons to consider this service for your brand:

1) COMPLIANCE – We’ve honed a robust format over the last 10+ years that has been presented and has held up to virtually all types of substantiation inquiries that our clients have faced. Claims substantiation is not optional – it is a legal requirement for your company. 

2) COPY WRITING – One of the biggest and most common mistakes we see is when brands write copy and make claims based on what competitors say. Do not make them fly blind and fall into this lazy trap – and put your company at risk. Our substantiation files include a main document that outlines your ingredients and the numerous claims that can be considered, as well as files containing the studies that would support those claims. We often use these files for creative kick off calls with writers to ensure they know the products that they are selling. 

3) PRODUCT DEVELOPMENT – We can create substantiation files for a new product, for and existing product, or for a product needing reformulation. In any case, our main substantiation document can be instrumental in giving your team a quick and easy method for dialing in doses, forms, combinations, delivery methods, etc. to ensure your product has maximum claims, uses the correct forms of ingredients, isn’t over-formulated and unnecessarily increasing product costs, and is safe and effective in your target populations. 

If you are interested in claims substantiation files that serve your legal requirements, but also serve your product development, advertising claims and angles, and bottom line, let’s discuss and get you into our schedule. Turnaround times are generally three to four weeks depending on your product. We have generous multiple-product discounting as well. Contact us today at experts@dietarysupplementexperts.com.

Final Nail in the CBD Coffin?!

Recently, the FDA gave a conclusion to the CBD story. In short, they reconfirmed that CBD is not allowed in dietary supplements or conventional foods, and confirmed that they do not intend to pursue rulemaking that would allow it. 

Will this “news” do anything to change the market flooded with these illegal products? Unlikely. There is a segment of the industry that has so far largely ignored the red flags such as the droves of FDA Warning Letters (lots of them), the scant science to give any credence to the claims (“but Big Brand X says it’s good for insomnia, pain, depression, COVID-19, etc.” is not substantiation), the fact that most legitimate manufacturers won’t touch CBD, the lack of banks to process the sales, the lack of networks that will run ads, the wacky labeling rules – aka violations (somehow isolated CBD = hemp extract), and so on. Many convinced that the all but irrelevant 2018 Farm Bill legalized CBD in supplements and foods, and so felt justified to join the mob of CBD sellers. 

Will FDA enforcement change? Time will tell. Probably just more of the same. Expect to see continued Warning Letters for products making disease claims, with reminders that CBD isn’t a legal dietary ingredient. 

DSE has dozens of clients working with CBD. Our advice generally has centered around risk mitigation – not making disease claims, not making unsubstantiated claims, labeling the products compliantly as possible (as if CBD were legal), and keeping a close eye on product quality. Risk of selling CBD products might be low, reward might be high, but make no mistake – CBD in supplements has not been legal, is not legal, and will not become legal according to the FDA. 

FDA Confusing on Plant Parts

For years, one of the most common violations cited in FDA Warning Letters has involved missing plant part(s) declarations for botanical ingredients. Specifically, the regulations require that the part(s) of the plant (e.g., root, leaves, seeds, etc.) from which a botanical dietary ingredient is derived be declared in the Supplement Facts panel. A few compliant examples: “Garlic bulb”, “Garlic (bulb)”, or “Garlic bulb extract”. The only exception for including plant parts would be for algae. 

While this violation is extremely common, it is also one of the easiest to comply with and prevent from ever becoming an issue for your brand. Raw material suppliers should be providing this critical information, it should be part of raw material specifications at the manufacturer, and should be communicated on all respective labels. However, some simplicity seems to be lost when it comes to raw materials using aerial parts, and that designation being declared on product labels. 

We’ve seen “aerial parts” listed on raw material data sheets indicating all above ground parts. We’ve seen 100s of labels using that plant parts declaration, and never really batted an eye about it being inaccurate or misleading. However, a series of FDA Warning Letters in the past few years have made us question the declaration, and even advise clients about it. 

Some FDA Warning Letter excerpts on this topic:

To ForYou, Inc.

Your Thin-Ergy AM and Thin-Ergy Boost products are misbranded within the meaning of section 403(s)(2)(C) of the Act [21 U.S.C. § 343(s)(2)(C)] because the label fails to identify the part of the plant (e.g., root, leaves) from which each botanical dietary ingredient in the product is derived, as required by 21 CFR 101.4(h)(1). For example, the labels fail to declare the specific part of certain plants that use the term “aerial parts.”

To BHP Holding, Inc. 

Your Neem Synergy and Cocktail Liposomal products are misbranded…in that the labels fail to identify the part of the plant (e.g., root, leaves) from which each botanical dietary ingredient in the product is derived…For example, those botanical dietary ingredients that identify the part of the plant as “aerial parts” fail to specify the exact aerial parts.

To R-Garden, LLC

Your Memory Formula, Herbal Blends Eyes System, Herbal Blends Liver Gallbladder System, Milk Thistle Formula, and Herbal Blends Prostate System products are each misbranded…because the label fails to identify the part of the plant (e.g., root, leaves) from which each botanical dietary ingredient in the product is derived, as required by 21 CFR 101.4(h)(1)….For your Herbal Blends Eyes System, “aerials” are not a specific plant part. 

To Marco Pharma International, LLC

Your Para A and Absinthium products are misbranded…in that each label fails to identify the part of the plant (e.g., root, leaves) from which each botanical dietary ingredient in the product is derived…For example, your Para A and Absinthium product labels fail to declare the specific part of certain plants that use the term “aerial part” or “aerial portion”.

To Let’s Talk Health, Inc. 

Your Agua Vitae “Water of Life,” Brain Booster, Prosta-Plex Plus, Diatrol Plus, and Menopause products are misbranded…because the labels fail to identify the part of the plant (e.g., root, leaves) from which each botanical dietary ingredient in the product is derived…The Menopause product label lists “aerial part” which is not a specific part of the plant for the alfalfa in the “Proprietary MenoRelief Complex.”

To TruVision Health, LLC

Your Complete™ Women’s Multivitamin product is misbranded…because the label fails to identify the part of the plant (e.g., root, leaves) from which each botanical dietary ingredient in the product is derived…We note the term “Horsetail Extract (Aerial Parts)” does not comply with this requirement.

Given the trend in citations for declaring plant parts as “aerial parts”, “aerial portion”, or “aerials”, it would seem that brands should be more specific in their plant part declarations in order to appease the FDA. As we advised clients of this, many of the conversations that followed were almost always similar. The question back was immediately, “Well what should we put instead, if our manufacturer and raw material supplier have documentation that aerial parts is accurate?” Our response to that was muddy at best – to declare individual parts as best you can. But of course, sometimes what would come back would be too few parts (e.g., stem and leaves) to accurately represent all above ground parts, or it would be too complex to fit onto a label, where a dozen or more parts would be revealed. Nothing seemed to rival the accuracy of simply “aerial parts”. 

Knowing that we’ve seen FDA review many labels listing “aerial parts”, many raw material specifications listing “aerial parts”, many MMRs and BPR listing “aerial part” without apparent issue, this was a challenging thing to comment on clearly. We have also seen FDA receive new dietary ingredient notifications for botanicals using aerial parts, and find “aerial parts” listed as a plant part in FDA’s Botanical Drug Development guidance document. And then we saw the recent Warning Letter sent:

To Western Herb Products, Inc. 

Your Wormwood/Aloes dietary supplement is misbranded…in that the labels fails to identify the appropriate part of the plant (e.g., root, leaves) from which each botanical dietary ingredient in the product is derived, as required by 21 CFR 101.4(h)(1). For example:

a. The label indicated that Artemisia absinthium is derived from the leaf part of the plant, however, the specification sheet indicated that the botanical ingredient is derived from the aerial parts, which include the entire plant parts that grow above the ground…The plant part declared on the product label must be consistent with the actual plant part identity as indicated on the specification sheet.

Reading this section of the Warning Letter seems to indicate that FDA here recognizes “aerial parts” to mean the entire plant parts grown above the ground – and also seems to indicate that the violation could be corrected by declaring “aerial parts” on this particular label. 

Going forward, unless we get some more clarity from FDA or otherwise – as long as our clients are declaring accurately “aerial parts”, we are not going to comment on it for change. This declaration does not seem to have a better alternative to match conciseness on a label. 

Tune Up Your FDA Compliance!

It’s difficult fix a problem if you don’t know there is one to begin with – which is the case with many clients we work with. So, we’ve compiled a brief set of checks that you can quickly and easily self-audit with. While very far from being all-inclusive, these checks touch on some of the lowest-hanging fruits and most common violations seen. If you recognize one or more with your brand, it doesn’t guarantee you are violating regulations, but it would be a strong indication that you have something to look at.

Red Flags

Labels:

  • Are any of your botanical plant parts declared as “aerial parts” or “herb”?
  • Are there any zeros (e.g., 0 mg or 0 g) in the Supplement Facts panel?
  • Are you missing a U.S. phone or address where adverse events can be reported?

Claims:

  • Are you making explicit or implied claims about COVID, flu, or cold?
  • Do you have any unqualified inflammation or pain claims?
  • Are you making claims about hangovers?

Manufacturing:

  • Do your certificates of analysis (COAs) list “by input” as the only testing method to ensure label claims specifications are met?
  • Is your manufacturer registered with the FDA?
  • Do you not have and follow your own set of written procedures (SOPs) for things not conducted by you manufacturer or other contracted partners (e.g., returned dietary supplements, product complaints, reserve samples, supplier qualification, etc.)?

Ingredients:

  • Does your product contain cannabidiol (CBD)?
  • Does your product contain n-acetyl l-cysteine (NAC)?
  • Does your product contain kratom?

Could you answer “yes” or even “I don’t know” to any of these? If so, it’s not necessarily a reason to panic, but you should be concerned. Sometimes brands take calculated risks because the potential reward might out-weight them. But other times, they take uncalculated risks because they are unaware, see other brands doing something, or they are just marketers that do not know or care about following the rules. In any case, we are here to help. If you have something questionable, we can help determine if you are at risk, explain to you why you are at risk, and help you make the corrective actions to reduce or remove the risk. Contact us today to get a free assessment of your situation.

Label Review Tools Part 2

If you are a frequent reviewer of dietary supplement labels, you have probably found that your speed and efficiency increase when you have your “tools” readily accessible. All the way back in 2014, we published the Part 1 to this article, and are finally making good on the Part 2. The previously named tools included 1) the regulations and guidance documents, 2) a calculator for percent Daily Values, and 3) the FDA Warning Letters published weekly. Here are three additional tools to use and where to get them.

Tool #4 – Herbs of Commerce
It is pretty tough to properly label botanical ingredients without this critical reference tool. In fact, 21 CFR 101.4(h) actually requires that the common or usual names of dietary ingredients that are botanicals (including fungi and algae) be consistent with the names standardized in Herbs of Commerce. It can be purchased through the American Herbal Products Association’s website here. You will be amazed to find how many “common” names used for botanicals are not technically appropriate for labeling.

Tool #5 – FDA’s high-resolution Supplement Facts panel examples
We share the link to this tool with clients and designers maybe more than anything else. And while you must have some knowledge of required formatting and when and where to use certain formats, the FDA’s High-Resolution Examples of Different Supplement Facts Labels in the New Format is invaluable for quickly viewing a range of Supplement Facts panel types. This is a far safer model for your own labels than competitor labels!

Tool #6 – A (NEW!!) % Daily Value calculator
Although this is the same tool we recommended in the Part 1 of this article, enough time has passed that the labeling regulations have been changed, and with them came many new Daily Values and even units of measure. So once again, if you are currently using a regular calculator for determining your declarations, you are wasting far too much time. Using a program such as Microsoft Excel, you can create your own spreadsheet, where you can enter in the label values for nutrients and it will give you the percentages. A proper and efficient one will be built so that all of the nutrients are already in the order that they must be declared on the label, the correct nomenclature is used, the defined units of measure are used, and the numbers are automatically rounded to the nearest whole percentages. Not up to building one or just need a better one? Our newest version can be downloaded for a small fee here.

Top Supplement Label Errors of 2020

By Curtis Walcker, M.S.
January 24, 2021

In 2020, we saw 20 FDA Warning Letters posted citing label violations for dietary supplements. We tallied up all of the violations cited and put them into a single chart. For the most part, these are the same violations we see year after year. However, there were a few things worth taking note of. Here is what we found:

What was familiar?
We do tracking and compiling of FDA Warning Letters each year, and with regard to label violations, everything was pretty familiar. FDA was able to grab the same old low-hanging fruits that brands still find challenges with. As with years previous – incorrect common or usual names, missing plant parts for botanicals, missing ingredient declarations, and incorrect use of bars and hairlines topped the chart with very high numbers. Things like zero claims, intervening material, and the use of footnotes that should not be present can typically be traced back to brands trusting the templated system-generated Supplement Facts panels supplied to them by their manufacturers, or worse – copying competitor labels. No matter what the reason behind errors, the Warning Letters get addressed to the brand on the bottle, and not manufacturers or competitors. Shoring up label compliance is definitely one of the fastest and easiest risk-reducers for any brand.

How did our client labels compare?
New client labels were very similar in terms of what issues we resolved, and frequency in which they occurred. The great thing that occurs with returning or existing clients is that within a few labels together, the client begins removing template errors across all of their labels proactively, so our reviews become more streamlined and focused on product-specific errors. For instance, once a client figures out that they were missing serious adverse event reporting information on a couple of labels, they go back and put it onto all labels.

What stuck out?
More than anything, this is why we track Warning Letters and violations the way we do. You can go read the laws and regulations all day long, but Warning Letters shed light on what the FDA is focusing on, and how they are interpreting things. While nothing was really new here, beyond the usual violations, these three stuck out:

  1. Trade names are not permitted within the Supplement Facts panel.

    This may come as a big surprise to virtually all brands…and manufactures…and raw material suppliers. However, it is the case. The information panel of a label generally bears the Supplement Facts panel, ingredient statement, and name/place of business, and major food allergen labeling when applicable. All of these items are regulated in terms of their contents, placement, and formatting. Adding anything beyond what is required, becomes at risk of being what the regulations refer to as “intervening material”. And anything intervening and not required by the regulations is generally not allowed.

    In the Warning Letter to Market America, Inc. for instance, FDA noted to them that referencing their trademarked ingredients (SunActive® and Quatrefolic®) within the Supplement Facts panel was not permitted – referring to it as intervening material.

    This does create a bit of a conundrum. A brand invests more into their product with trademarked ingredients, and they want to let their consumers know. However, for FDA compliance, the Supplement Facts panel should not be that marketing vehicle. There are many other places more suitable on the label or in the labeling for marketing callouts.

  2. “Herb” and “aerial parts” are not acceptable plant parts to declare for botanicals.

    Again, probably surprising to a lot of brands. We see this come through on labels weekly. Plant part(s) declared for botanicals need to be specific. Understandably, FDA told R-Garden, LLC that “Cleavers herb” was inadequate, as “herb” is not a plant part. Less understandable, however, ForYou, Inc. and BHP Holdings, Inc. were told that “aerial parts” was also inadequate. The industry tends to use “aerial parts” when plant parts used consist of all parts above ground – much like “whole plant” is used when all parts are used. The challenge in labeling aerial parts one-by-one is that the lists could become long and ultimately be more misleading when parts are left out of the list. This is one we’d like to see some more clarity from the FDA on what exactly they are looking for.

  3. If a footnote in the Supplement Facts panel is not required, it is not allowed.

    This one is usually just a template error, usually passed along by a manufacturer, but a risk nonetheless. We see many Supplement Facts panels with both of the typical footnotes, “Daily Value not established” and “Percent Daily Values are based on a 2,000 calorie diet”. However, either one is only required and only allowed when it applies based on what is declared. FDA let LifeHealth Science know this, when they sent them a Warning Letter stating that their footnote was not permitted, as nothing declared required it.

If you recognize any of these errors in your own labels, or are unsure, we are here to help. We offer very affordable label compliance review service, fast turnaround times, and bulk discounting for multiple labels. Contact us today!